About Constellation Pharma
Constellation Pharma is a Healthcare company based in Cambridge (United States) founded in 2008, and was acquired by MorphoSys in June 2021. Developer of drugs in the field of epigenetics. Constellation Pharma has raised $349.37 million across 9 funding rounds from investors including Fidelity Investments, MorphoSys and Genentech. The company has 142 employees. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Constellation Pharma was founded in 2008 and is based in Cambridge, United States. Operations are centered in the biotechnology sector, where drugs are developed in the field of epigenetics. The pipeline features inhibitors of bromodomain and extra-terminal proteins, which regulate gene expression, along with small molecules targeting EZH2, a histone methyltransferase in the PRC2 complex. Focus is placed on advancing these therapies through research and development.
- Headquarters Cambridge, United States
- Employees 142
- Stage Acquired
- SectorsHealthcare
- Website constellationpharma.com
- Social LinkedIn X
- Acquired by MorphoSys (Jun 2021)
- Total Equity Funding$349.37M (USD)
in 9 rounds
- Latest Funding Round$65M (USD), Post-IPO
Oct 2019
- InvestorsFidelity Investments
& 18 more
- Employee Count142
- Acquired byMorphoSys
(Jun 2021)
Funding Insights of Constellation Pharma
Constellation Pharma has successfully raised a total of $349.37M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $65 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $349.37M
- Total Rounds 9
- Last Round Post-IPO — $65M
- First Round $32M
(Apr 2008)
- Investors Count 18
All 9 funding rounds of Constellation Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | $65M | Post-IPO | – | – | |
| Apr 2018 | $100M | Series E | – | Deerfield, Fidelity Investments | |
| Sep 2016 | $24.3M | Series D | – | – | – |
| Dec 2015 | $55.82M | Series D | – | Third Rock Ventures, TCG | – |
| Aug 2014 | $5M | Series C | – | – | – |
| Jan 2012 | $95M | Series C | – | – | |
| May 2011 | $15M | Series B | – | Third Rock Ventures, SR One | – |
| May 2010 | $22.25M | Series B | – | SR One, Altitude | |
| Apr 2008 | $32M | Series A | – | – |
19 investors in total: 19 institutional.
Investors in Constellation Pharma
Constellation Pharma has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, MorphoSys and Genentech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com |
Investor details for Constellation Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Constellation Pharma
23 people are tracked at Constellation Pharma (12 in leadership, 8 in board & advisors, 3 in team); the tracked headcount is 142.
| Name | Role | Group |
|---|---|---|
Patrick Trojer | Chief Scientific Officer | Leadership |
Jigar Raythatha | President & CEO | Leadership |
Jike Cui | Director of Computational Biology | Leadership |
zehua chen | Associate Director, Computational Biology | Leadership |
Michael Cooper | Chief Medical Officer | Leadership |
Morgan Harris, PharmD | Associate Director Clinical Scientist | Leadership |
Barbara Krebs-Pohl | Chief Integration Officer | Leadership |
Ashlesh Sheth | Sr Director, Drug Product Development/Tech Ops | Leadership |
Jatin Patel | Senior Vice President, Head of CMC | Leadership |
Jignesh Patel | Associate Director Product Development & Tech Ops | Leadership |
Sandra Klein | Clinical Scientist, Associate Director | Leadership |
Irina Apostolou | Sr. Director, Head of Immuno-Oncology | Leadership |
David Allis | Founder | Board & advisors |
James E. Audia | Director | Board & advisors |
Mark A. Goldsmith | Chairman | Board & advisors |
Yang Shi | Founder | Board & advisors |
Scott Braunstein | Director | Board & advisors |
Steven L. Hoerter | Director | Board & advisors |
Elizabeth G. Tréhu | Director | Board & advisors |
Danny Reinberg | Founder | Board & advisors |
3 more people are available in the full profile.
Complete people profiles for Constellation Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Constellation Pharma
5 dated milestones of Constellation Pharma across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Constellation Pharma is founded.
- Funding First funding round of $32.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $65.0M.
- Exit Acquired by MorphoSys.
Competitors of Constellation Pharma
Constellation Pharma has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Constellation Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Constellation Pharma
Websites that share an audience with Constellation Pharma (constellationpharma.com).
Websites whose visitors overlap most with Constellation Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
betterbabybook.com | betterbabybook.com | 100% | – | ||
 georgefebish.wordpress.com | georgefebish.wordpress.com | 100% | – | ||
bbs.ebiotrade.com | bbs.ebiotrade.com | 99% | – | ||
epigenetics-international.com | epigenetics-international.com | 70% | #706,102 | – | |
| facebook.com | 65% | 12.1B | #3 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Constellation Pharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Constellation Pharma
Complete news archive for Constellation Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Constellation Pharma
Constellation Pharma was founded in 2008.
Constellation Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Constellation Pharma is a funded company, having raised a total of $349.37M across 9 funding rounds to date. The company's 1st funding round was a Series A of $32M, raised on Apr 2008.
Constellation Pharma has 142 employees.
Constellation Pharma was founded in 2008 and is based in Cambridge, United States. Operations are centered in the biotechnology sector, where drugs are developed in the field of epigenetics. The pipeline features inhibitors of bromodomain and extra-terminal proteins, which regulate gene expression, along with small molecules targeting EZH2, a histone methyltransferase in the PRC2 complex. Focus is placed on advancing these therapies through research and development.
Constellation Pharma's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Constellation Pharma has 19 investors. Key investors include Fidelity Investments, MorphoSys, Genentech, Orbimed, and The Column Group.
Yes. Constellation Pharma was acquired by MorphoSys in June 2021.